Wall Street analyst estimates for Cellectar Biosciences, Inc. (CLRB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.88 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.56 | ||
| 2026-08-13 | $-0.57 | $-0.52 | -9.6% |
| 2026-05-14 | $-1.33 | $-1.89 | +29.4% |
| 2026-03-04 | $-0.53 | $-1.19 | +55.5% |
| 2025-11-13 | $-1.41 | $-1.91 | +26.2% |
| 2025-08-14 | $-3.39 | $-3.60 | +5.8% |
| 2025-05-13 | $-3.90 | $-5.11 | +23.7% |
| 2025-03-13 | $-0.01 | $-0.38 | +97.4% |
Valuation Ratios
| Price / Book | 0.98 |
| EV / EBITDA | 0.59 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $356665 | $1.5M | $82265 | $189360 | 0 | 0 | 0 | 0 | 0 | $213597 |
| Gross Profit | -$356665 | -$1.5M | -$82265 | -$189360 | 0 | 0 | 0 | 0 | 0 | -$213597 |
| Research & Development | $4.8M | $9.5M | $6.8M | $9.0M | $10.1M | $17.6M | $19.2M | $27.3M | $26.1M | $11.5M |
| Selling, General & Admin | $4.7M | $4.1M | $4.8M | $5.0M | $5.1M | $6.5M | $9.6M | $11.7M | $25.6M | $11.5M |
| Operating Expenses | $9.4M | $13.6M | $11.7M | $14.0M | $15.3M | $24.1M | $28.8M | $39.0M | $51.8M | $22.8M |
| Operating Income | -$9.4M | -$13.6M | -$13.3M | -$14.2M | -$15.3M | -$24.1M | -$28.8M | -$39.0M | -$51.8M | -$23.0M |
| EBITDA | -$9.1M | -$12.1M | -$13.2M | -$13.9M | -$14.9M | -$24.0M | -$31.7M | -$42.6M | -$44.2M | -$21.6M |
| Interest Expense | $7897 | $16605 | $29687 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$6.2M | -$13.6M | -$13.2M | -$14.1M | -$15.1M | -$24.1M | -$31.9M | -$42.8M | -$44.5M | -$21.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -$60000 | -$60000 | $66000 | 0 |
| Net Income | -$6.2M | -$13.6M | -$13.2M | -$14.1M | -$15.1M | -$24.1M | -$31.8M | -$42.8M | -$44.6M | -$21.8M |
| EPS | $-6420.00 | $-3210.00 | $-1567.96 | $-550.86 | $-228.55 | $-130.35 | $-135.18 | $-104.99 | $-36.52 | $-8.35 |
| EPS (Diluted) | $-6420.00 | $-3210.00 | $-1567.96 | $-550.86 | $-228.55 | $-130.35 | $-135.18 | $-104.99 | $-41.89 | $-8.35 |
| Shares Outstanding (Diluted) | $1455 | $4677 | $9873 | $25583 | $66042 | $185052 | $235188 | $407385 | $1.2M | $2.6M |
Price
| Price | $2.35 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AEON · BOLT · CING · EVGN · IMNN · LYRA · MBIO
Explore sector: Healthcare · Biotechnology
More sections of CLRB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks